Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Certara (CERT) stock in plain English

Free brief · no signupStart here
CERTPublished Nov 16, 2026
Certara Inc
Healthcare · Health Information Services
Sells biosimulation software and specialized consulting services to biopharmaceutical companies.
Assets:
Simcyp platformPhysiologically based pharmacokinetic simulator used across the pharmaceutical industry
Phoenix softwareWidely adopted standard for pharmacokinetic and pharmacodynamic data analysis
Specialized workforceEmploys hundreds of doctorate-level scientists and regulatory affairs specialists
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

61
OPS ScoreOperating finances
Latest quote
-4.47%$10.68
$1.63B
n/a (loss)
$398.33M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was CERT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Certara (CERT) do?

Certara Inc (CERT) is a U.S.-listed company in Healthcare (Health Information Services). What it does: Sells biosimulation software and specialized consulting services to biopharmaceutical companies. Uses computer modeling and biosimulation software to predict how drugs behave in the human body. It is worth $1.63B on the market and sold $398.33M over the last year.

Market cap
$1.63B
P/E ratio
None (reported a loss)
Annual sales
$398.33M
Sector
Healthcare
Industry
Health Information Services
Brief updated
Nov 16, 2026

Brands and businesses behind CERT

  • Simcyp: Physiologically based pharmacokinetic modeling software that earns through recurring annual software subscription licenses.
  • Phoenix: Pharmacokinetic data analysis software sold to researchers through software licenses.
  • Pinnacle 21: Data validation software that earns subscription revenue helping drug developers prepare regulatory data submissions.
  • BaseCase: Visual communication software that earns subscription revenue helping pharmaceutical companies present evidence to healthcare payers.

CERT’s flags, in plain English

Each flag is a number from Certara’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Insiders Hold

Insiders own 36.3% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Stupid Cash

Can pay this year's bills 2.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 31% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -1.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about CERT

How big is Certara?

Certara’s market cap is $1.63B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $398.33M: what customers paid the company over the last year, before any costs.

What is CERT’s P/E ratio?

CERT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with CERT?

Revenue depends heavily on the research and development spending levels of biotechnology and pharmaceutical clients. That is one risk on Certara’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Certara’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CERT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card